Trendlines Group Ltd. – Company Snapshot
The Trendlines Group Ltd. is listed on the Singapore Exchange under the ticker TRENDLINES GROUP LTD/THE. It operates within the financial services sector, specifically in capital markets. The company was founded in 2007 and maintains offices in Israel (M.P. Misgav, Tel Aviv), Beijing, China, and Singapore.
Core Business
Trendlines Group Ltd. functions as an innovation commercialization firm that specializes in the incubation and seed/start‑up investment of early‑stage medical and agricultural technologies. Its service portfolio includes:
- Business incubation
- Partner and channel development
- Market strategy formulation
- Business plan development
- Research and development support
- Commercialization activities
- Business development and finance strategy
- Administrative services
- Marketing communications
The firm targets minimum investment amounts of SGD 0.06 million for portfolio companies. Exits are pursued through mergers and acquisitions, public listings, or other dispositions. The company mitigates investment risk by combining its own capital with government funding, and it maintains active involvement across the full lifecycle of its portfolio companies, from technology development to business building.
Financial Profile (as of 2026‑10‑22)
| Item | Value |
|---|---|
| Close Price | SGD 0.049 |
| 52‑Week High | SGD 0.084 |
| 52‑Week Low | SGD 0.045 |
| Market Capitalisation | SGD 77 023 800 |
| P/E Ratio | 6.41 |
The share price has declined from its 52‑week high of SGD 0.084 to a low of SGD 0.045, resulting in a close price of SGD 0.049. The price‑earnings ratio of 6.41 indicates the market’s valuation relative to earnings, though the company’s earnings profile is not disclosed in the provided data.
Recent Market Activity
No company‑specific news has been reported in the input for the dates surrounding 2026‑10‑22 to 2026‑10‑24. The only available news items relate to cryptocurrency price analysis for XRP and Cardano, which do not involve Trendlines Group Ltd. Consequently, there are no recent operational or financial developments to report for the company.
Outlook
Given the absence of new public announcements, the company’s trajectory will continue to depend on its ongoing investment and incubation activities in the medical and agricultural technology sectors. Market participants should monitor the company’s future releases for updates on portfolio performance, new investment rounds, and exit strategies.
